Shares of MyoKardia Inc. (NASDAQ:MYOK) traded up 21% during trading on Tuesday . The company traded as high as $16.35 and last traded at $16.20, with a volume of 57,920 shares trading hands. The stock had previously closed at $13.39.

A number of analysts have commented on the stock. Zacks Investment Research cut shares of MyoKardia from a “hold” rating to a “sell” rating in a research note on Wednesday. Credit Suisse Group AG reissued a “buy” rating on shares of MyoKardia in a research report on Tuesday. Cowen and Company reissued an “outperform” rating and issued a $24.00 price objective on shares of MyoKardia in a research report on Monday, March 21st. Finally, Wedbush reissued an “outperform” rating and issued a $22.00 price objective on shares of MyoKardia in a research report on Friday, March 18th. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $21.33.

The firm’s 50-day moving average is $13.46 and its 200 day moving average is $11.17. The company’s market cap is $471.05 million.

MyoKardia (NASDAQ:MYOK) last posted its quarterly earnings data on Thursday, May 12th. The company reported ($0.32) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.53) by $0.21. On average, equities research analysts predict that MyoKardia Inc. will post ($1.56) EPS for the current fiscal year.

MyoKardia, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is engaged in the development of therapies for treating cardiovascular diseases. The Company focuses on developing and discovering therapies for hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.